Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720

EPMA Journal

Godfrey Grech¹  Nigel Borg¹  Anthony G Fenech²  Vanessa Petroni²  Christian Saliba¹  Shawn Baldacchino¹ 

[1] Department of Pathology, Medical School, University of Malta, Msida MSD2090, Malta;Department of Clinical Pharmacology and Therapeutics, University of Malta, Msida MSD2090, Malta

关键词: Personalised medicine;    Therapeutic groups;    PP2A;    Predictive biomarkers;   

Others  :  804435
DOI  :  10.1186/1878-5085-5-3

 received in 2013-12-13, accepted in 2014-01-09,  发布年份 2014

【 摘 要 】

Background

The most commonly used biomarkers to predict the response of breast cancer patients to therapy are the oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2). Patients positive for these biomarkers are eligible for specific therapies such as endocrine treatment in the event of ER and PgR positivity, and the monoclonal antibody, trastuzumab, in the case of HER2-positive patients. Patients who are negative for these three biomarkers, the so-called triple negatives, however, derive little benefit from such therapies and are associated with a worse prognosis. Deregulation of the protein serine/threonine phosphatase type 2A (PP2A) and its regulatory subunits is a common event in breast cancer, providing a possible target for therapy.

Methods

The data portal, cBioPortal for Cancer Genomics was used to investigate the incidence of conditions that are associated with low phosphatase activity. Four (4) adherent human breast cancer cell lines, MDA-MB-468, MDA-MB-436, Hs578T and BT-20 were cultured to assess their viability when exposed to various dosages of rapamycin or FTY720. In addition, RNA was extracted and cDNA was synthesised to amplify the coding sequence of PPP2CA. Amplification was followed by high-resolution melting to identify variations.

Results and conclusion

The sequence of PPP2CA was found to be conserved across a diverse panel of solid tumour and haematological cell lines, suggesting that low expression of PPP2CA and differential binding of inhibitory PPP2CA regulators are the main mechanisms of PP2A deregulation. Interestingly, the cBioPortal for Cancer Genomics shows that PP2A is deregulated in 59.6% of basal breast tumours. Viability assays performed to determine the sensitivity of a panel of breast cancer cell lines to FTY720, a PP2A activator, indicated that cell lines associated with ER loss are sensitive to lower doses of FTY720. The subset of patients with suppressed PP2A activity is potentially eligible for treatment using therapies which target the PI3K/AKT/mTOR pathway, such as phosphatase activators.

【 授权许可】

   
2014 Baldacchino et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ: Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22(8):1736-1747.
• [3]Schnitt SJ: Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 2010, 23:S60-S64.
• [4]Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7(1–2):4-13.
• [5]Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY, Tokuda Y: Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 2007, 98(12):1889-1892.
• [6]Leevers SJ, Vanhaesebroeck B, Waterfield MD: Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999, 11(2):219-225.
• [7]Saito K, Scharenberg AM, Kinet JP: Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk. J Biol Chem 2001, 276(19):16201-16206.
• [8]Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT: Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277(5325):567-570.
• [9]Tang B, Mano H, Yi T, Ihle JN: Tec kinase associates with c-kit and is tyrosine phosphorylated and activated following stem cell factor binding. Mol Cell Biol 1994, 14(12):8432-8437.
• [10]Russillo M, Di Benedetto A, Metro G, Ferretti G, Papaldo P, Cognetti F, Mottolese M, Fabi A: Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile? J Clin Oncol 2011, 29(20):2834-2835. author reply 2835
• [11]Liu L, Chen L, Luo Y, Chen W, Zhou H, Xu B, Han X, Shen T, Huang S: Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. PLoS One 2010, 5(5):e10578.
• [12]Peyssonnaux C, Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001, 93(1–2):53-62.
• [13]Silverstein AM: Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci 2002, 99(7):4221-4226.
• [14]Grech G, Blazquez-Domingo M, Kolbus A, Bakker WJ, Mullner EW, Beug H, von Lindern M: Igbp1 is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting erythroid differentiation. Blood 2008, 112(7):2750-2760.
• [15]Calin GA, Iasio MG, Caprini E, Vorechovsky I, Natali PG, Sozzi G, Croce CM, Barbanti-Brodano G, Russo G, Negrini M: Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000, 19:1191-1195.
• [16]Ruediger R, Ruiz J, Walter G: Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice. Mol Cell Biol 2011, 31(18):3832-3844.
• [17]Janssens V, Goris J, Van Hoof C: PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005, 15(1):34-41.
• [18]Wang SS, Esplin ED, Li JL, Huang L, Evans GA: Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998, 282(5387):284-287.
• [19]Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T, Saji S: Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 2000, 47(2):268-271.
• [20]Chou H-C, Chen C-H, Lee H-S, Lee C-Z, Huang G-T, Yang P-M, Lee PH, Sheu JC: Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma. Cancer Lett 2007, 253(1):138-143.
• [21]Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, Giamas G: The regulatory roles of phosphatases in cancer. Oncogene 2013. doi:10.1038/onc.2013.80
• [22]Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, DeCaprio JA, Hahn WC: The tumor suppressor PP2A Aβ regulates the RalAGTPase. Cell 2007, 129(5):969-982.
• [23]Wong LL, Zhang D, Chang CF, Koay ES: Silencing of the PP2A catalytic subunit causes HER-2/neu positive breast cancer cells to undergo apoptosis. Exp Cell Res 2010, 316(20):3387-3396.
• [24]Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T: Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008, 10(6):R101. BioMed Central Full Text
• [25]Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, Pandolfi PP, Cantley LC: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer cell 2009, 16(2):115-125.
• [26]Ma Y, Hu C, Riegel AT, Fan S, Rosen EM: Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol 2007, 21(8):1905-1923.
• [27]Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, Obata T, Ebina Y, Kashiwagi A, Olefsky JM: Protein phosphatase 2A negatively regulates insulin’s metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3 T3-L1 adipocytes. Mol Cell Biol 2004, 24(19):8778-8789.
• [28]Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, Yang Q: Negative regulation of AKT activation by BRCA1. Cancer Res 2008, 68(24):10040-10044.
• [29]Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998, 2(3):317-328.
• [30]Filonenko V, Tytarenko R, Azatjan S, Savinska L, Gaydar Y, Gout I, Usenko VS, Lyzogubov VV: Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors. Exp Oncol 2004, 26(4):294-299.
• [31]Zhou X: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10(20):6779-6788.
• [32]Stål O, Pérez-Tenorio G, Åkerberg L, Olsson B, Nordenskjöld B, Skoog L, Rutqvist LE: Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 2003, 5(2):R37-R44. BioMed Central Full Text
• [33]Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
• [34]Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J: CIP2A Is associated with human breast cancer aggressivity. Clin Cancer Res 2009, 15(16):5092-5100.
• [35]Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J: CIP2A Inhibits PP2A in human malignancies. Cell 2007, 130(1):51-62.
• [36]Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ: Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms’ tumor. J Am Soc Nephrol 1998, 9:1873-1880.
• [37]Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery 2012, 2(5):401-404.
• [38]Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fairley S, Fitzgerald S, Gil L, García-Girón C, Gordon L, Hourlier T, Hunt S, Juettemann T, Kähäri AK, Keenan S, Komorowska M, Kulesha E, Longden I, Maurel T, McLaren WM, Muffato M, Nag R, Overduin B, Pignatelli M, Pritchard B, Pritchard E, et al.: Ensembl 2013. Nucleic Acids Res 2013, 41(D1):D48-D55.
• [39]Wang J, Li W, Li L, Yu X, Jia J, Chen C: CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011, 33(3):290-298.
• [40]Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, Ristimäki A: Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011, 105(7):989-995.
• [41]Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, Lin CC, Hsu YN, Wang HW, Chen KF: CIP2A Is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 2012, 16(5):1037-1047.
• [42]Vaarala MH, Väisänen MR, Ristimäki A: CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010, 29(1):136. BioMed Central Full Text
• [43]Laine A: The Role of an Oncoprotein CIP2a in Breast Carcinoma. Turku: University of Turku; 2013.
• [44]Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J: CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012, 31(39):4266-4278.
• [45]Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8(5):355-368.
• [46]Kong M, Ditsworth D, Lindsten T, Thompson CB: α4 is an essential regulator of PP2A phosphatase activity. Mol Cell 2009, 36(1):51-60.
• [47]Sablina , Hector M, Colpaert N, Hahn WC: Identification of PP2A complexes and pathways involved in cell transformation, Volume 70. 24th edition. 2010, 10474-10484.
• [48]Feng Z, Levine AJ: The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010, 20(7):427-434.
• [49]Westermarck J, Hahn WC: Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008, 14(4):152-160.
• [50]Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL: CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010, 29(47):6257-6266.
• [51]Xiang , Jia , Sherris , Li , Wang , Lu D, Yang Q: Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene 2011, 30(21):2443-2450.
• [52]Keen JC, Zhou QH, Park BH, Pettit C, Mack KM, Blair B, Brenner K, Davidson NE: Protein phosphatase 2A regulates estrogen receptor (ER) expression through modulation of ER mRNA stability. J Biol Chem 2005, 280(33):29519-29524.
• [53]Gorski JJ, Kennedy RD, Hosey AM, Harkin DP: The complex relationship between BRCA1 and ER in hereditary breast cancer. Clin Cancer Res 2009, 15(5):1514-1518.
• [54]Satheesha S, Cookson VJ, Coleman LJ, Ingram N, Madhok B, Hanby AM, Suleman CA, Sabine VS, Macaskill EJ, Bartlett JM, Dixon JM, McElwaine JN, Hughes TA: Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol Cancer 2011, 10(1):19. BioMed Central Full Text
• [55]Golubnitschaja O, Costigliola V, EPMA: General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European association for predictive, preventive and personalised medicine. EPMA J 2012, 3(1):14. BioMed Central Full Text
• [56]Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH: Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J 2013, 4(1):6. BioMed Central Full Text